Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $3.9 million.

  • Voyager Therapeutics' Net Cash Flow fell 8921.64% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.7 million, marking a year-over-year decrease of 23321.8%. This contributed to the annual value of $3.8 million for FY2024, which is 11278.63% up from last year.
  • Voyager Therapeutics' Net Cash Flow amounted to $3.9 million in Q3 2025, which was down 8921.64% from -$30.8 million recorded in Q2 2025.
  • Voyager Therapeutics' 5-year Net Cash Flow high stood at $169.4 million for Q1 2023, and its period low was -$179.0 million during Q3 2023.
  • Its 5-year average for Net Cash Flow is -$2.9 million, with a median of $3.4 million in 2025.
  • In the last 5 years, Voyager Therapeutics' Net Cash Flow plummeted by 11967333.33% in 2022 and then skyrocketed by 107286.7% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Net Cash Flow (Quarter) stood at $6.0 million in 2021, then crashed by 64.77% to $2.1 million in 2022, then skyrocketed by 68.32% to $3.5 million in 2023, then crashed by 1264.96% to -$41.2 million in 2024, then surged by 109.54% to $3.9 million in 2025.
  • Its Net Cash Flow was $3.9 million in Q3 2025, compared to -$30.8 million in Q2 2025 and $3.4 million in Q1 2025.